Klimek, Ludger
Klimek, Felix
Bergmann, Christoph
Hagemann, Jan
Cuevas, Mandy
Becker, Sven
Funding for this research was provided by:
Universitätsklinikum Tübingen
Article History
Accepted: 12 December 2023
First Online: 22 January 2024
Conflict of interest
: J. Hagemann received grants from Novartis Pharma, Sanofi, GSK and HAL Allergy, outside the submitted work. C. Bergmann has received honoraria from Allergy Therapeutics/Bencard, UK/Germany; Germany; GlaxoSmithKline (GSK), UK; HAL, Netherlands, and Sanofi, Germany, outside the submitted work. M. Cuevas has received honoraria from AstraZeneca, GSK, Sanofi and Novartis, outside the submitted work. L. Klimek has received research grants from Allergy Therapeutics/Bencard, UK/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; ASIT Biotech, Belgium; AstraZeneca, Sweden, Bionorica, Germany; Biomay, Austria, Boehringer Ingelheim, Germany, Circassia, USA; Stallergene, France; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Hartington, Spain; Lofarma, Italy; MEDA/Mylan, Sweden/USA; Novartis, Switzerland, Leti, Spain; Roxall, Germany; GlaxoSmithKline (GSK), UK, and Sanofi, France and/or acted in an advisory capacity for the aforementioned pharmaceutical companies. LK is editor of the <i>Allergo Journal</i> and <i>Allergo Journal International</i> and is the current President of the AeDA (Association of German Allergists) and Vice President of the EAACI. S. Becker has received honoraria for lectures, consulting and research from ALK Abéllo, Allergopharme, HALAllergie, Bencard Allergie, Allergy Therapeutics, Thermo Fisher Scientific, Novartis, AstraZeneca, Sanofi Genzyme, GSK, MSD, Mylan, Viatris, Karl Storz GmbH, Altamira, Auris Medical, Smart Reporting, Stryker, Helix Biopharm and BMBF. F. Klimek has no conflicts of interest in connection with this work.